Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq slides to near one-month low as AI rout deepens
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent oil slips as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $38.14 +3.39%
Revenue Growth %: -13.0%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
NTRP, FMCB, LOOP, More
Revenue Growth %: -13.0%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
NTRP, FMCB, LOOP, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.24), $0.08 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $16.31 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FMC tumbles 35% after slashing Q3 outlook over weak demand and inventory issues
- Active options: AVGO INTC MU DELL ASTS SOFI NBIS MSFT CIFR
- Tesla shares fall amid inflation data and rate concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
